TY  - JOUR 
AU  - S.A., Jacobs
AU  - A., Robidoux
AU  - J., Abraham
AU  - J.M., Perez-Garcia
AU  - N., La Verde
AU  - J.M., Orcutt
AU  - M.E., Cazzaniga
AU  - F., Piette
AU  - Antolín Novoa, Silvia
AU  - E., Aguirre
AU  - J., Cortes
AU  - A., Llombart-Cussac
AU  - S., Di Cosimo
AU  - R.S., Kim
AU  - H., Feng
AU  - C., Lipchik
AU  - P.C., Lucas
AU  - A., Srinivasan
AU  - Y., Wang
AU  - N., Song
AU  - P.G., Gavin
AU  - A.D., Balousek
AU  - S., Paik
AU  - C.J., Allegra
AU  - N., Wolmark
AU  - K.L., Pogue-Geile
PY  - 2019
SN  - 1465-5411
UR  - http://hdl.handle.net/20.500.11940/16020
AB  - PURPOSE: The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2(+)) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly...
LA  - eng
TI  - NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
DO  - 10.1186/s13058-019-1196-y
T2  - BREAST CANCER RESEARCH
M2  - 133
KW  - CHUAC
VL  - 21.
ER  -